Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Female and male subjects who must be healthy and must be:~1. Between 18 and 60 years of age inclusive and who have given their written informed consent;~2. Available for all visits and telephone calls scheduled for the study;~3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;~4. For female subjects, having a negative urine pregnancy test.~Exclusion Criteria:~Individuals not eligible to be enrolled in the study are those:~1. who are breastfeeding;~2. who have a personal history of Neisseria meningitidis infection, typhoid fever, rabies, or any flavivirus infection (e.g., Japanese encephalitis, tick-borne encephalitis, yellow fever, dengue fever, West Nile virus infection);~3. who have been immunized with any of the study vaccines within the last five years as determined by medical history and/or vaccination card;~4. who have received investigational agents or vaccines within 30 days prior to enrollment or who expect to receive an investigational agent or vaccine prior to completion of the study;~5. who have received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.~   (Exception: Influenza vaccine may be administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization);~6. who have received an anti-malaria drug, up to 2 months prior to the study;~7. who have experienced, within the 7 days prior to enrollment, significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or have experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment;~8. who have any serious acute, chronic or progressive disease such as:~   * history of cancer~  * complicated diabetes mellitus~  * advanced arteriosclerotic disease~  * autoimmune disease~  * HIV infection or AIDS~  * blood dyscrasias~  * congestive heart failure~  * renal failure~  * severe malnutrition (Note: Subjects with mild asthma are eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids are not eligible for enrollment);~9. who have epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome;~10. who have a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including but not limited to latex allergy, egg allergy, antibiotic allergy, chicken proteins or gelatin allergy;~11. who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):~    * receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose \> 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);~   * receipt of immunostimulants;~   * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study;~12. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;~13. who have myasthenia gravis; thyroid or thymic disorders,~14. who have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives;~15. who are part of the study personnel or close family members of those conducting this study.~16. for whom a long-term stay (≥ 1 month) was planned in Africa, Latin America, or Asia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- TF+YF (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
- TF + YF + MenACWY-CRM197 (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
- JE + Rabies (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
- JE + Rab + MenACWY-CRM197 (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
- Rabies (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
- MenACWY-CRM197 (Combined) (Type: ACTIVE_COMPARATOR): Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).